
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<FONT SIZE=3 ><A HREF="#04ATA1695_2">QuickLinks</A></FONT>
<font size=3> -- Click here to rapidly navigate through this document</font>
<!-- TOC_END -->
<P ALIGN="RIGHT"><FONT SIZE=2><A
NAME="ke1695_exhibit_1.1"> </A>
<A NAME="toc_ke1695_1"> </A>
<BR></FONT><FONT SIZE=2><B>Exhibit&nbsp;1.1    <BR>    </B></FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><B>EXCHANGE AGREEMENT  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;THIS EXCHANGE AGREEMENT (the "</FONT><FONT SIZE=2><I>Agreement</I></FONT><FONT SIZE=2>"), dated as of December&nbsp;17, 2004, between Life Therapeutics Limited
(f/k/a Gradipore Limited), a corporation organized under the laws of the Commonwealth of Australia (the "</FONT><FONT SIZE=2><I>Company</I></FONT><FONT SIZE=2>"), and Serologicals Finance Company, a
Delaware corporation (the "</FONT><FONT SIZE=2><I>Holder</I></FONT><FONT SIZE=2>"). </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>WITNESSETH
</FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS,
Holder previously sold all of the issued and outstanding shares of its wholly-owned subsidiary, LifeSera,&nbsp;Inc. (f/k/a Serologicals Specialty Biologics,&nbsp;Inc.), a
Delaware corporation ("</FONT><FONT SIZE=2><I>LifeSera</I></FONT><FONT SIZE=2>"), to Life Gels,&nbsp;Inc. (f/k/a Gradipore,&nbsp;Inc.), a Delaware corporation
("</FONT><FONT SIZE=2><I>LG</I></FONT><FONT SIZE=2>"), and wholly-owned subsidiary of the Company (the "</FONT><FONT SIZE=2><I>Acquisition</I></FONT><FONT SIZE=2>"); </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS,
as consideration for the Acquisition, Holder received, and currently holds, two promissory notes, the first in the amount of One Million Five Hundred Thousand Dollars (US
$1,500,000.00), a copy of which is attached hereto as </FONT><FONT SIZE=2><I>Exhibit&nbsp;A</I></FONT><FONT SIZE=2> (the "</FONT><FONT SIZE=2><I>Short Term Old Note</I></FONT><FONT SIZE=2>"), and
the second in the amount of Eleven Million Eight Hundred Three Thousand Eight Hundred Sixty-Seven Dollars (US $11,803,867.00), a copy of which is attached hereto as </FONT> <FONT SIZE=2><I>Exhibit&nbsp;B</I></FONT><FONT SIZE=2> (the "</FONT><FONT
SIZE=2><I>Long Term Old Note</I></FONT><FONT SIZE=2>", together with the Short Term Old Note, the
"</FONT><FONT SIZE=2><I>Old Notes</I></FONT><FONT SIZE=2>") each made by LifeSera, LifeSera Nevada,&nbsp;Inc. (f/k/a Serologicals Nevada,&nbsp;Inc.), a Nevada corporation
("</FONT><FONT SIZE=2><I>Nevada</I></FONT><FONT SIZE=2>"), LifeSera Business Trust (f/k/a Serologicals Business Trust), a Nevada business trust
("</FONT><FONT SIZE=2><I>LBT</I></FONT><FONT SIZE=2>"), LifeSera Investments, LLC (f/k/a Serologicals Investments, LLC), a Georgia limited liability company
("</FONT><FONT SIZE=2><I>LLC</I></FONT><FONT SIZE=2>"), LifeSera Management Partnership, LP (f/k/a Serologicals Management Partnership, LP), a Delaware limited partnership
("</FONT><FONT SIZE=2><I>LP</I></FONT><FONT SIZE=2>"), Allegheny Biologicals,&nbsp;Inc., a Pennsylvania corporation ("</FONT><FONT SIZE=2><I>Allegheny</I></FONT><FONT SIZE=2>"), LG and Life
Therapeutics Plasma Holdings,&nbsp;Inc. (f/k/a Gradipore Plasma Holdings,&nbsp;Inc.), a Delaware corporation ("</FONT><FONT SIZE=2><I>GPH</I></FONT><FONT SIZE=2>" and together with LifeSera,
Nevada, LBT, LLC, LP, Allegheny and LG, each a "</FONT><FONT SIZE=2><I>Maker</I></FONT><FONT SIZE=2>" and collectively, the "</FONT><FONT SIZE=2><I>Makers</I></FONT><FONT SIZE=2>"), in connection
with the Acquisition; </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS,
subject to the terms and subject to the conditions of this Agreement, the Holder desires to forgive any outstanding principal plus accrued but unpaid interest under the Old
Notes in consideration for (i)&nbsp;a new secured promissory note issued by the Company and the Makers in the amount of Seven Million Eight Hundred Thousand Dollars (US $7,800,000.00), a copy of
which is attached hereto as </FONT><FONT SIZE=2><I>Exhibit&nbsp;C</I></FONT><FONT SIZE=2> (the "</FONT><FONT SIZE=2><I>Note</I></FONT><FONT SIZE=2>"), which Note shall be secured as more fully set
forth in that certain Amended and Restated Security Agreement, of even date herewith (the "</FONT><FONT SIZE=2><I>Security Agreement</I></FONT><FONT SIZE=2>"), a copy of which is attached hereto as </FONT> <FONT
SIZE=2><I>Exhibit&nbsp;D</I></FONT><FONT SIZE=2>, (ii)&nbsp;a non-exclusive license to use certain proprietary technology of the Company pursuant to the license set forth
in Article&nbsp;V of this Agreement (the "</FONT><FONT SIZE=2><I>License</I></FONT><FONT SIZE=2>") and (iii)&nbsp;the Release (as defined below); </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS,
Holder acknowledges that the Company and the other Makers are entering into this Agreement to, along with other good and valuable consideration, strengthen their respective
balance sheets and financial positions to better enable the Company to engage in new financing arrangements through the issuance of equity or debt securities or otherwise. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NOW,
THEREFORE, in consideration of the mutual covenants and agreements herein set forth and each act done pursuant hereto, the parties hereto, intending to be legally bound, do hereby
represent, warrant, covenant and agree as follows: </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><B>ARTICLE I<BR>
DEFINITIONS  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In this Agreement or in the Note, as applicable, the following terms have the meanings specified or referred to in this Article&nbsp;I and are equally
applicable to both the singular and plural forms: </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>1933 Act</I></FONT><FONT SIZE=2>" means the Securities Act of 1933, as amended. </FONT></P>

<HR NOSHADE>
<P style='page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2149161",CP="SEROLOGICALS CORPORATION",DN="2",CHK=757390,FOLIO='blank',FILE='DISK013:[04ATA5.04ATA1695]KE1695A.;7',USER='SSTANSE',CD='23-DEC-2004;09:46' -->
<A NAME="page_ke1695_1_2"> </A>
<BR>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Acts</I></FONT><FONT SIZE=2>" means the 1933 Act and any applicable state securities laws. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Affiliate</I></FONT><FONT SIZE=2>" means any Person (a)&nbsp;that directly or indirectly, through one or more intermediaries, controls or is controlled by, or
is under common control with, the Person involved, including, without limitation, officers, directors and individuals in like capacities, (b)&nbsp;that directly or beneficially owns or holds 5% or
more of any equity interest in the Person involved, or (c)&nbsp;5% or more of whose voting securities (or in the case of a Person which is not a corporation, 5% or more of any equity interest) is
owned directly or beneficially by the Person involved. As used herein, the term "control" shall mean possession, directly or indirectly, of the power to direct or to cause the direction of the
management or policies of a Person, whether through ownership of equity interests, by contract or otherwise. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>ASX</I></FONT><FONT SIZE=2>" means the Australian Stock Exchange Limited ABN 98 008 624 691 and the stock market operated by it. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Business</I></FONT><FONT SIZE=2>" means the business of (a)&nbsp;collecting, refining, processing, testing, validating, labeling, packaging, marketing,
advertising, administering, selling and distributing the Inventory, (b)&nbsp;operating the Donor Centers and (c)&nbsp;conducting any other business engaged in by LifeSera and the Subsidiaries on
the date of this Agreement. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Closing Documents</I></FONT><FONT SIZE=2>" means this Agreement, the Note, the Security Agreement and the Release (as defined below). </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Donor Centers</I></FONT><FONT SIZE=2>" means each of those source plasma donor collection centers listed on Schedule&nbsp;A of that certain Stock Purchase
Agreement, dated as of December&nbsp;19, 2003, by and among the Company, LG, Holder and Serologicals Corporation. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Indebtedness</I></FONT><FONT SIZE=2>" means all indebtedness for borrowed money (including money obligations) maturing one year or more from the date of creation
or incurrence thereof or renewable or extendible at the option of the debtor to a date one year or more from the date of creation or incurrence thereof, all indebtedness under revolving credit
arrangements extending over a year or more, all capitalized lease obligations and all guarantees of any of the foregoing. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Inventory</I></FONT><FONT SIZE=2>" means all inventories of raw materials, work-in-process, finished goods, fluids, components, parts,
packaging materials and other materials related thereto which are held at, or are in transit from or to, the locations at which the Business is conducted, or located at customers' premises on
consignment or elsewhere, in each case, which are used or useful by LifeSera, the Subsidiaries or any Affiliates thereof in the conduct of the Business, including but not limited to, all human
polyclonal plasma containing blood typing reagents, clinical diagnostic antibodies, all naturally occurring disease associated antibodies, and all plasma containing Rh immune globulin
(Anti-D), anti-hepatitis B immune globulin (HBs), anti-rabies immune globulin (Rabies), vaccinia immune globulin (VIG), intravenous immune globulin (IVIG),
BDP-I, BDP-II, BDP-III, Antisera and D-Slide, and any other source plasma, specialty or
non-specialty antibodies and specialty biologic components, as well as any other therapeutic or diagnostic products. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>One Month LIBOR</I></FONT><FONT SIZE=2>" as referenced in the Note means the rate of interest, for any calendar month beginning on the first day of such calendar
month and ending on the last day of such calendar month, which is equal to the offered rate for deposits in U.S. dollars of amounts comparable to the principal amount of the Note, which rate appears
on that page of Bloomberg reporting service, or such similar service as determined by the Holder, that displays British Bankers' Association interest settlement rates for deposits in U.S. Dollars, as
of 11:00&nbsp;A.M. (London, England time) two (2)&nbsp;business days prior to the first day of such calendar month; </FONT><FONT SIZE=2><I>provided</I></FONT><FONT SIZE=2>, that if no such
offered rate appears on such page, the rate used for such calendar month will be the per annum rate of interest determined consistent with this definition in good faith by the Holder. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>2</FONT></P>

<HR NOSHADE>
<P style='page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=2,EFW="2149161",CP="SEROLOGICALS CORPORATION",DN="2",CHK=3389,FOLIO='2',FILE='DISK013:[04ATA5.04ATA1695]KE1695A.;7',USER='SSTANSE',CD='23-DEC-2004;09:46' -->
<A NAME="page_ke1695_1_3"> </A>
<BR>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Person</I></FONT><FONT SIZE=2>" means any individual, sole proprietorship, partnership, joint venture, trust, unincorporated association, corporation, limited
liability company, entity or governmental entity (whether federal, state, county, city or otherwise and including, without limitation, any instrumentality, division, agency or department thereof). </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Release</I></FONT><FONT SIZE=2>" means the Release Agreement, dated as of the date hereof, made by the Company and the Makers in favor of the Holder and its
Affiliates, a copy of which is attached hereto as </FONT><FONT SIZE=2><I>Exhibit&nbsp;E</I></FONT><FONT SIZE=2>. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Replacement Stock Certificates</I></FONT><FONT SIZE=2>" means certificates representing the issued and outstanding shares of the capital stock of Life Sera and
Nevada. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Shares</I></FONT><FONT SIZE=2>" means such ordinary shares of the Company, which are in the same class of those ordinary shares that are quoted on ASX, as are
transferred to the Holder pursuant to Section&nbsp;1 of the Note. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Subsidiaries</I></FONT><FONT SIZE=2>" means Nevada, LBT, LLC, LP, Allegheny, collectively. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><B>ARTICLE&nbsp;II<BR>
EXCHANGE  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.1</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Exchange of Promissory Notes.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Holder hereby agrees to assign and transfer to the Company at the Closing (as
defined below), and the Company hereby agrees to accept and acquire from Holder at the Closing all right, title and interest in and to the indebtedness represented by the Old Notes in consideration
and in exchange for the issuance by the Company to such Holder of the Note and the execution and delivery by the Company and the Makers of the Release. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.2</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Closing and Deliveries.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The cancellation and exchange provided for in Section&nbsp;2.1 above is taking
place simultaneously with the execution and delivery of this Agreement (the "Closing"). At the Closing, the Company shall duly and validly deliver to Holder the duly executed Closing Documents,
against delivery by the Holder of the Old Notes and cancellation of same by the Company. Simultaneously with the Closing, the Company shall pay to the Holder the sum of U.S. $5,000.00 to reimburse the
Holder for its out-of-pocket expenses in connection with the consummation of the transactions contemplated by this Agreement. The Holder shall, within 90&nbsp;days following
the Closing, submit to the Company (i)&nbsp;invoices with respect to its out-of-pocket expenses and (ii)&nbsp;a check in the amount of any excess of its
out-of-pocket expenses over the expenses represented by such invoices or a request for payment of any out-of-pocket expenses incurred by the Holder in
excess of U.S. $5,000.00. The Company will pay any such invoice promptly following its receipt thereof. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><B>ARTICLE III<BR>
REPRESENTATIONS AND WARRANTIES OF HOLDER  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Holder hereby represents and warrants to the Company that: </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.1</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Authority; Ownership.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Except as provided in the next sentence, Holder owns all right, title and interest to
the Old Notes free and clear of any claim, suit, proceeding, call, commitment, trust, proxy, restriction, limitation, security interest, pledge, lien or encumbrance of any kind or nature whatsoever,
and has full power and authority to transfer and assign the same hereunder to the Company. Holder has pledged the Old Notes to JPMorgan Chase Bank, as Administrative Agent (the
"</FONT><FONT SIZE=2><I>Agent</I></FONT><FONT SIZE=2>"), pursuant to that certain Credit Agreement, dated as of October&nbsp;14, 2004, among Serologicals Corporation, the lenders named therein and
the Agent. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.2</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Investment Representations.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;Holder
understands that the Note is not, and any Shares of the Company that may be issued to Holder in connection with a Share Payment (as defined in the Note) may not
be, </FONT></P>

</UL>
<P ALIGN="CENTER"><FONT SIZE=2>3</FONT></P>

<HR NOSHADE>
<P style='page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=3,EFW="2149161",CP="SEROLOGICALS CORPORATION",DN="2",CHK=872733,FOLIO='3',FILE='DISK013:[04ATA5.04ATA1695]KE1695A.;7',USER='SSTANSE',CD='23-DEC-2004;09:46' -->
<A NAME="page_ke1695_1_4"> </A>
<UL>

<P><FONT SIZE=2>registered
under the Acts in reliance on an exemption from registration under the 1933 Act pursuant to Section&nbsp;4(2) thereof for the transaction contemplated by this Agreement and the issuance
of the Note hereunder; </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;Holder
understands that the Note (and any Shares of the Company that may be issued to Holder in connection with a Share Payment) may not be sold, transferred or
otherwise disposed of without registration under the 1933 Act or an exemption therefrom, and that in the absence of an effective registration statement covering the Note or Shares or an available
exemption from registration under the 1933 Act, the Note and any Shares issued in connection with a Share Payment must be held indefinitely; and </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;Holder
is an "</FONT><FONT SIZE=2><I>Accredited Investor</I></FONT><FONT SIZE=2>" as that term is defined in Rule&nbsp;501 of Regulation&nbsp;D promulgated under
the 1933 Act. </FONT></P>

</UL>
<P ALIGN="CENTER"><FONT SIZE=2><B>ARTICLE IV<BR>
REPRESENTATIONS AND WARRANTIES OF THE COMPANY  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company hereby represents and warrants to Holder that: </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.1</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Valid Issuance.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;When, and if, issued in accordance with the terms of the Note, the Shares will be duly and
validly issued, fully paid and nonassessable, free from pre-emptive rights, quoted on ASX, able to be sold on ASX without restriction, free of restrictions of transfer other than pursuant
to the terms thereof and applicable state and federal securities laws and the applicable securities laws of the Commonwealth of Australia, and any other contractual restrictions entered into by Holder
and ranking equally with and carry all rights attaching to the existing issued ordinary shares of the Parent at the time of their issue. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.2</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Organization.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Company is a corporation duly organized and validly existing under the laws of the
Commonwealth of Australia, and has all requisite corporate power and authority to execute, deliver and perform the Closing Documents. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.3</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Authority.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;All corporate action on the part of the Company and its officers, directors and stockholders
necessary for the authorization, execution, delivery and performance of all obligations of the Company
under this Agreement, the Security Agreement and the Release and for the authorization, issuance and delivery of the Note being exchanged under this Agreement and the issuance of Shares to the Holder
pursuant to the terms of the Note has been taken or will be taken prior to the Closing, or in the case of the issuance of Shares to the Holder, prior to such issuance. This Agreement, the Note, the
Security Agreement and the Release, when executed and delivered, shall constitute valid and legally binding obligations of the Company, enforceable in accordance with their respective terms. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.4</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;No Approvals or Conflict.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;No consent, approval or authorization of or declaration to or filing with any
Person is required for the valid authorization, execution and delivery by the Company of this Agreement, the Note, the Security Agreement, the Release or any Shares or for its consummation of the
transactions contemplated hereby and thereby or for the valid authorization, issuance and delivery of the Note and the Shares. The execution, delivery and performance by the Company of this Agreement,
the Note, the Security Agreement, the Release and the Shares and its consummation of the transactions contemplated herby and thereby will not (a)&nbsp;contravene, conflict with or violate any
provision of any law applicable to the Company or any of its properties or assets, except where any such contravention, conflict or violation would not reasonably be likely to have a Material Adverse
Effect on the Company (as defined below) or (b)&nbsp;contravene, conflict with or result in any breach of any of the terms, conditions or provisions of, or constitute a default or give rise to any
right of termination, cancellation or acceleration under, or result in the creation of any lien upon any of the properties or assets of the Company or under its certificate of incorporation or bylaws
or any material </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>4</FONT></P>

<HR NOSHADE>
<P style='page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=4,EFW="2149161",CP="SEROLOGICALS CORPORATION",DN="2",CHK=176963,FOLIO='4',FILE='DISK013:[04ATA5.04ATA1695]KE1695A.;7',USER='SSTANSE',CD='23-DEC-2004;09:46' -->
<A NAME="page_ke1695_1_5"> </A>
<BR>

<P><FONT SIZE=2>contract
to which it is a party except where any such contravention, conflict or breach would not reasonably be likely to have a Material Adverse Effect on the Company. The term
"</FONT><FONT SIZE=2><I>Material Adverse Effect</I></FONT><FONT SIZE=2>" shall mean an event or series of events that, in the aggregate, would reasonably be likely to have a material adverse effect
on the assets, liabilities, financial condition, business or results of operations of the Company or the ability of the Company to operate in the ordinary course of business or to perform its
obligations under the terms of this Agreement, the Note, the Security Agreement or the Release. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><B>ARTICLE&nbsp;V<BR>
LICENSE  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.1</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Technology.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Company owns valuable, patented technology relating to tangential flow membrane
electrophoresis (the "</FONT><FONT SIZE=2><I>Gradiflow Technology</I></FONT><FONT SIZE=2>"), including patent rights and patents that may from time to time issue with claims covering Life
Therapeutics' patented Gradiflow Device (the "Gradiflow Device") or improvements thereto and other information (the "Related Technology") relating to use of the Gradiflow Technology for the recovery
of proteins and other charged molecules from solutions containing such molecules (collectively, the Gradiflow Technology and the Related Technology shall be referred to herein as the
"</FONT><FONT SIZE=2><I>Company Technology</I></FONT><FONT SIZE=2>"). </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.2</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;License.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Company hereby grants to Holder a non-exclusive worldwide license to use the
Company Technology solely for its internal business use related to cell culture separation and solely for experiments, developmental work, and/or tests requiring the recovery of molecules from
solutions containing such molecules. Holder may not use the Company Technology for commercial production and Holder may not exchange for value products produced by the Company Technology or use the
products to produce other products in exchange for value. Holder shall not perform or offer to perform commercial services of any kind using the Company Technology, including, without limitation, the
reporting of the results of Holder's use of the Company Technology for consideration. Holder agrees not to take any action that will infringe upon the Company Technology or Company's exclusive right
to modify, enhance and develop the Company Technology, including, without limitation, Company's right to develop methods and applications for use with the Company Technology. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Should
Holder desire to use the Company Technology for other purposes, such as in trade or commerce or to produce products that are to be used in trade or commerce, and/or should Holder
wish to purchase or lease the Gradiflow Device from the Company, Holder must obtain an additional license from Company. Should Holder wish to develop separation methods and applications relating to an
existing use of the Company Technology or a use in development by the Company, Holder agrees to notify the Company of such proposed development. Holder further agrees that the developed intellectual
property shall be owned solely by the Company. Holder agrees to execute and deliver to the Company such instruments as the Company deems necessary to vest in Company the sole ownership of and all
exclusive rights in and to any such developed intellectual property. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.3</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Ownership.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Holder acknowledges that the Company Technology is owned by the Company and/or its licensors and
Holder does not receive any ownership rights to the Company Technology in connection with the license granted herein. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.4</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Transfer of Rights.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Holder may not transfer or assign its license rights set forth herein without the
express written consent of the Company, which consent may be withheld in the Company's sole discretion. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.5</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Term.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;This license grant, and any and all rights, and obligations set forth herein with respect to such
license, shall become effective on the Closing Date of this Agreement and shall continue in effect for a period expiring on the later to occur of (i)&nbsp;the repayment in full of the Note and
(ii)&nbsp;the fifth anniversary of the date hereof. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>5</FONT></P>

<HR NOSHADE>
<P style='page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=5,EFW="2149161",CP="SEROLOGICALS CORPORATION",DN="2",CHK=319784,FOLIO='5',FILE='DISK013:[04ATA5.04ATA1695]KE1695A.;7',USER='SSTANSE',CD='23-DEC-2004;09:46' -->
<A NAME="page_ke1695_1_6"> </A>
<BR>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.6</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Confidentiality.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Holder acknowledges that the Company Technology contains confidential and proprietary
information of the Company. Holder agrees to (i)&nbsp;hold the Company Technology in the strictest confidence, (ii)&nbsp;not disclose the Company Technology to any third party for any purpose, and
(iii)&nbsp;use the same security measures with respect to the Company Technology as Holder uses to protect its own confidential information, but no less than commercially reasonable measures to
protect the confidentiality of the Company Technology. Holder agrees and acknowledges that any breach of the provisions regarding ownership or confidentiality of the Company Technology shall cause the
Company irreparable harm and the Company may obtain injunctive relief without the requirement to post a bond as well as seek all other remedies available to the Company in law and in equity in the
event of breach or threatened breach of such provisions. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.7</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;No Warranty.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;THE COMPANY TECHNOLOGY IS PROVIDED "AS IS". THE COMPANY MAKES NO WARRANTIES WHATSOEVER WITH
RESPECT TO THE COMPANY TECHNOLOGY WHETHER EXPRESS, IMPLIED OR STATUTORY INCLUDING, WITHOUT LIMITATION, THE IMPLIED WARRANTIES OF TITLE, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE OR OTHER
SIMILAR WARRANTIES. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.8</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Limitation of Liability.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;IN NO EVENT SHALL THE COMPANY OR ANY OF ITS LICENSORS BE LIABLE TO HOLDER, ITS
AFFILIATES OR ANY THIRD PARTY FOR ANY INDIRECT, INCIDENTAL, PUNITIVE, SPECIAL OR CONSEQUENTIAL DAMAGES, EVEN IF THE COMPANY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. THE COMPANY'S TOTAL
LIABILITY RELATED TO ALL COMPANY TECHNOLOGY PROVIDED TO HOLDER HEREUNDER REGARDLESS OF THE CLAIM, SHALL NOT EXCEED THE FEES PAID BY HOLDER TO THE COMPANY FOR THE LICENSE RIGHTS GRANTED TO HOLDER
HEREUNDER. Holder agrees that the Company shall not be liable for any damages arising out of a use of the Company Technology that is inconsistent with the Company's specifications or recommendations. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><B>ARTICLE&nbsp;VI<BR>
MISCELLANEOUS  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.1</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Performance.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Holder agrees that it shall diligently observe and perform or cause to be observed and
performed all obligations to be observed or performed under the Closing Documents. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.2</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Securities Filings.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Within the prescribed time after the Closing, the Company shall file all documents and
take all proceedings required to be taken by it to permit the Note and, when applicable, the Shares to be issued to the Holder in compliance with applicable Australian, U.S. federal and state
securities laws and the listing rules of the ASX. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.3</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Replacement of Lost Security.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Upon receipt of evidence reasonably satisfactory to the Company of the loss,
theft, destruction or mutilation of the Note or any of the Shares and, in the case of any such loss, theft or destruction of the Note or any of the Shares (in each case a "</FONT><FONT SIZE=2><I>Lost
Security</I></FONT><FONT SIZE=2>"), upon receipt by the Company or its transfer agent of an indemnity reasonably satisfactory to the Company, which may in any event include the posting of a bond in an
amount satisfactory to cover the amount of Shares or Note alleged to be lost, stolen or destroyed or, in the case of any such mutilation, upon the surrender and cancellation of the Note or the
mutilated Shares, the Company, at its expense, shall execute and deliver, in lieu thereof, a new Note or new Shares, as the case may be, of like tenor and dated the date of such Lost Security;
provided that the Company (or its transfer agent) shall have the right to require Holder to execute and deliver such other documentation that may be is reasonably requested by Company in order to
provide adequate assurance with respect to the Lost Security. Any Lost Security in lieu of which any such new Note or new Shares, as the case may be, has been so executed and delivered by the Company
shall not be deemed to be an outstanding Note or outstanding Shares, as the case may be. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>6</FONT></P>

<HR NOSHADE>
<P style='page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=6,EFW="2149161",CP="SEROLOGICALS CORPORATION",DN="2",CHK=195844,FOLIO='6',FILE='DISK013:[04ATA5.04ATA1695]KE1695A.;7',USER='SSTANSE',CD='23-DEC-2004;09:46' -->
<A NAME="page_ke1695_1_7"> </A>
<BR>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.4</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Notices.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;All notices, demands and other communications provided for or permitted hereunder or under the
Note, the Security Agreement or the Release shall be made in writing and shall be by registered or certified first-class mail, return receipt requested, by next day delivery through a recognized
national courier or personal delivery: </FONT></P>

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE WIDTH="63%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="TOP">
<TD COLSPAN=2><FONT SIZE=2>(a) If to the Company:</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="48%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=2><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="48%"><FONT SIZE=2>Life Therapeutics Limited<BR>
P.O. Box 6126 Frenchs Forest<BR>
22 Rodborough Road<BR>
NSW 2086, Australia<BR>
Attention: John Manusu &amp; Hari Nair<BR>
Telecopy: (612) 9436-2907</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="3%"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD WIDTH="42%"><BR><FONT SIZE=2> with a copy to:</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="48%"><FONT SIZE=2><BR>
Buchanan Ingersoll PC<BR>
1776 K Street, N.W., Suite 800<BR>
Washington, D.C. 20006-2365<BR>
Attention: Edward John Allera, Esq.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=2><FONT SIZE=2><BR>
(b) if to the Holder, to:</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="48%"><FONT SIZE=2><BR>
Serologicals Corporation<BR>
5655 Spalding Drive<BR>
Norcross, Georgia 30092<BR>
Attention: Vice President, General Counsel</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="3%"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD WIDTH="42%"><BR><FONT SIZE=2> with a copy to:</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="48%"><FONT SIZE=2><BR>
King &amp; Spalding LLP<BR>
191 Peachtree Street, N.E.<BR>
Atlanta, Georgia 30303-1763<BR>
Attention: G. Roth Kehoe, Esq.</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
such notice, communication or delivery will be deemed given or made (a)&nbsp;on the fifth (5th) business day after it is mailed by registered or certified mail, (b)&nbsp;on the
first (1st) business day after delivery to an appropriate customer service representative if sent by next day delivery through a recognized national courier, or (c)&nbsp;on the date of delivery if
delivered in person. Any party may change its address for notice purposes by giving written notice to the other parties in the manner specified above. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.5</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Entire Agreement.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;This Agreement shall be binding upon and shall inure to the benefit of the parties hereto
and their respective successors, heirs, executors and administrators. The parties hereto may execute this Agreement in any number of counterparts, each of which when executed and delivered, shall be
an original, but all of which when taken together shall constitute one and the same instrument. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.6</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Maintenance of Authorized Shares; Replacement Stock Certificates.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Company at all times until the Note is
repaid in full shall have authorized and reserved, and shall keep available and free from preemptive rights, a sufficient number of Shares to provide for the issuance of Shares in payment of the
principal amount of the Note to the extent contemplated by the Note. Within 30&nbsp;days of the date of the Closing, the Company shall deliver the Replacement Stock Certificates to the Holder. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.7</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Governing Law.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;This Agreement shall be interpreted in accordance with the laws of the State of Delaware,
without regard to any jurisdiction's conflict of law provisions. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>[</FONT><FONT
SIZE=2><I>signatures follow</I></FONT><FONT SIZE=2>] </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>7</FONT></P>

<HR NOSHADE>
<P style='page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=7,EFW="2149161",CP="SEROLOGICALS CORPORATION",DN="2",CHK=128977,FOLIO='7',FILE='DISK013:[04ATA5.04ATA1695]KE1695A.;7',USER='SSTANSE',CD='23-DEC-2004;09:46' -->
<A NAME="page_ke1695_1_8"> </A>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN
WITNESS WHEREOF, the parties have duly executed this Exchange Agreement as of the day and year first above written. </FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="TOP">
<TD WIDTH="44%"><FONT SIZE=2>COMPANY:</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=2><FONT SIZE=2>LIFE THERAPEUTICS LIMITED</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="44%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2><BR>
By:</FONT></TD>
<TD WIDTH="45%"><FONT SIZE=2><BR>
/s/&nbsp;&nbsp;</FONT><FONT SIZE=2>JOHN MANUSU</FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="44%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2>Name:</FONT></TD>
<TD WIDTH="45%"><FONT SIZE=2>John Manusu</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="44%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2>Title:</FONT></TD>
<TD WIDTH="45%"><FONT SIZE=2>Authorized Officer</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="44%"><FONT SIZE=2><BR>
HOLDER:</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=2><FONT SIZE=2><BR>
SEROLOGICALS FINANCE COMPANY</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="44%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2><BR>
By:</FONT></TD>
<TD WIDTH="45%"><FONT SIZE=2><BR>
/s/&nbsp;&nbsp;</FONT><FONT SIZE=2>HAROLD W. INGALLS</FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="44%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2>Name:</FONT></TD>
<TD WIDTH="45%"><FONT SIZE=2>Harold W. Ingalls</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="44%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2>Title:</FONT></TD>
<TD WIDTH="45%"><FONT SIZE=2>President</FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<P ALIGN="CENTER"><FONT SIZE=2>8</FONT></P>

<HR NOSHADE>
<P style='page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=8,EFW="2149161",CP="SEROLOGICALS CORPORATION",DN="2",CHK=930941,FOLIO='8',FILE='DISK013:[04ATA5.04ATA1695]KE1695A.;7',USER='SSTANSE',CD='23-DEC-2004;09:46' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<P><br><A NAME="04ATA1695_2">QuickLinks</A><br></P><!-- TOC_BEGIN -->
<UL>
<FONT SIZE=2><A HREF="#toc_ke1695_1">Exhibit 1.1</A></FONT><BR>
</UL>
<!-- SEQ=,FILE='QUICKLINK',USER=SSTANSE,SEQ=,EFW="2149161",CP="SEROLOGICALS CORPORATION",DN="2" -->
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>

